Recurrent Gastrointestinal Stromal Tumors in the Imatinib Mesylate Era: Treatment Strategies for an Incurable Disease. (30th November 2017)

• Record Type: Journal Article
• Authors: Platoff, Rebecca M.; Morano, William F.; Marconcini, Luiz; DeLeo, Nicholas; Mapow, Beth L.; Styler, Michael; Bowne, Wilbur B.
• Other Names: De la Garza Jaime Academic Editor.
• Is Part Of: Case reports in oncological medicine. Volume 2017(2017)
• Publication Date: 2017-11-30
• Subjects: Oncology -- Periodicals; Tumors -- Periodicals; Oncology -- Case studies -- Periodicals; Neoplasms; Oncology; Tumors; Electronic journals; Periodicals; Case studies; Periodicals; Case Reports; Fulltext; Internet Resources; Periodicals; 616.994
• DOI: 10.1155/2017/8349090
• Languages: English
• ISSNs: 2090-6706

Abstract

Abstract : Introduction . Recurrence of gastrointestinal stromal tumors (GISTs) after surgical resection and imatinib mesylate (IM) adjuvant therapy poses a significant treatment challenge. We present the case of a patient who underwent surgical resection after recurrence and review the current literature regarding treatment. Case Presentation . A 58-year-old man with a large intra-abdominal jejunal GIST was treated with complete surgical resection followed by IM. The patient experienced disease recurrence 3.5 years later and underwent IM dose escalation and reresection. Conclusion . Current strategies to treat recurrent GIST include dose escalation, modifying adjuvant tyrosine kinase inhibitor therapy, and surgery. High-level evidence will be required to better define the combinatory roles of tyrosine kinase inhibitor therapy, guided by molecular profiling, and surgery in the management of recurrent GIST.